Overview

A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer

Status:
Completed

Trial end date:
2021-05-12

Target enrollment:

Participant gender:

Summary

This is an international multi-center, prospective, open-label, randomized, adaptive design phase 3 trial of the cancer stem cell pathway inhibitor napabucasin plus standard bi-weekly FOLFIRI versus standard bi-weekly FOLFIRI in patients with previously treated metastatic colorectal cancer (CRC).

Phase:

Phase 3

Details

Lead Sponsor:

Boston Biomedical, Inc
Sumitomo Dainippon Pharma Oncology, Inc

Treatments:

Bevacizumab
Camptothecin
Fluorouracil
Irinotecan
Leucovorin